Selected patients can benefit more from the management of etoposide and platinum-based chemotherapy and thoracic irradiation-a retrospective analysis of 707 small cell lung cancer patients

作者：Shoubo Cao, Jin Shi, Jing Shen, Jingyan Cao, Hua Zhang, Qingwei Meng, Chunyan Wang, Aiqi Zhang, Pei Zhang, Yan Yu · 发表于：Oncotarget · 年份：2016 · DOI：10.18632/oncotarget.14395 · 被引用次数：25 · 研究领域：Lung Cancer Research Studies、Neuroendocrine Tumor Research Advances、Lung Cancer Treatments and Mutations

// Shoubo Cao 1, * , Shi Jin 1, * , Jing Shen 1 , Jingyan Cao 1 , Hua Zhang 1 , Qingwei Meng 1 , Chunyan Wang 1 , Aiqi Zhang 1 , Pei Zhang 1 , Yan Yu 1 1 Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China * Shoubo Cao and Shi Jin contributed equally to this work and should be considered co-first authors Correspondence to: Yan Yu, email: yuyan@ems.hrbmu.edu.cn Keywords: small cell lung cancer, prognostic factors, subgroup analysis, inflammation, survival Received: June 29, 2016     Accepted: December 05, 2016     Published: December 31, 2016 ABSTRACT The management of small cell lung cancer (SCLC) has reached a plateau. Etoposide and platinum-based chemotherapy plus thoracic irradiation remain the standard treatment strategy for SCLC. Our study aims to assess the potential prognostic factors of patients treated with etoposide and platinum-based chemotherapy and explore which group of patients can benefit more from standard treatment strategies. On univariate analysis, age>65 years, male patients, KPS (Karnofsky Performance Status)≤80 points, positive smoking history, anemia, lymphocyte counts≤1.65×10 9 /L, neutrophil to lymphocyte ratio (NLR)>3.18, lymphocyte to monocyte ratio (LMR)≤2.615, lactate dehydrogenase (LDH)>216.5 U/L, alkaline phosphatase (ALP)>119.5 U/L, absence of surgery, absence of thoracic irradiation, chemotherapy cycles<4, metastatic sites≥2 and exten...